Amgen Purchase Of Horizon Given Nod By Ftc
Date
9/1/2023 10:11:11 AM
(MENAFN- Baystreet.ca)
Amgen Purchase of Horizon Given Nod by FTC The federal Trade Commission on Friday said it has reached a deal with drug giant Amgen (NASDAQ:AMGN) to allow the company's $27.8-billion purchase of Horizon Therapeutics (NASDAQ:HZNP) to move forward.
The FTC filed a lawsuit in May seeking to block the acquisition, arguing that the deal would“stifle competition” in the Pharmaceutical industry. But Amgen first moved to buy Horizon in December 2022 in an effort to gain access to the latter's rare disease assets, including the thyroid eye disease therapy Tepezza.
The buyout was quick to attract regulatory and political scrutiny for its potential antitrust issues.
In its lawsuit, the FTC said that the deal would allow Amgen to“entrench the monopoly positions” of Horizon's fast-growing medications, including Tepezza, and Krystexxa, a gout medicine.
Specifically, the agency said, Amgen would be able to offer rebates on its existing drugs to pressure insurers and pharmacy benefit managers into favoring the two Horizon products, a strategy known as“cross-market bundling.”
The FTC claimed California-based Amgen has a history of leveraging its drug portfolio to gain advantages over potential rivals.
Amgen is slated to present at the 2023 Wells Fargo Healthcare Conference on Wednesday. Amgen will also present at the Citi Global Healthcare Conference on Thursday.
AMGN shares hiked $2.33 to $258.68, while those for HZNP shares gained $2.82, or 2.5%, to $115.56.
MENAFN01092023000212011056ID1106996175
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.